INmune Bio falls after mid-stage trial for Alzheimer's drug to remain on hold

Inmune Bio

18/12/2023 22:14

** Shares of drug developer INmune Bio Inc  INMB.O  fall
~15% to $9.80 after the bell
    ** Co says it received notification that the mid-stage trial
of its Alzheimer's disease drug in the U.S. remains on full
clinical hold by the FDA pending a request for additional
information on long-term potency 
    ** INMB will provide additional information before the end
of 2023
    ** In the U.S., the previously identified clinical hold
issues have been successfully addressed - co
    ** The trial was first put on clinical hold in May last year
    ** The trial is open in Australia, Canada, UK, Poland,
France and Spain and is expected to open soon in several
additional EU countries
    ** Stock up ~81% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))